Show simple item record

dc.contributor.authorSholl, Lynette Marie
dc.contributor.authorXiao, Yun
dc.contributor.authorJoshi, Victoria
dc.contributor.authorYeap, Beow Yong
dc.contributor.authorCioffredi, Leigh-Anne
dc.contributor.authorJackman, David M
dc.contributor.authorLee, Charles
dc.contributor.authorJanne, Pasi Antero
dc.contributor.authorLindeman, Neal I.
dc.date.accessioned2017-05-18T15:42:11Z
dc.date.issued2010
dc.identifier.citationSholl, Lynette M., Yun Xiao, Victoria Joshi, Beow Y. Yeap, Leigh-Anne Cioffredi, David M. Jackman, Charles Lee, Pasi A. Jänne, and Neal I. Lindeman. 2010. “EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry.” American Journal of Clinical Pathology 133 (6) (June): 922–934. doi:10.1309/ajcpst1cthzs3psz.en_US
dc.identifier.issn0002-9173en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:32705642
dc.description.abstractAbout 10% of patients with non–small cell lung carcinoma (NSCLC) respond to epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs). More than 75% of “responders” have activating mutations in EGFR. However, mutation analysis is not widely available, and proposed alternatives (in situ hybridization and immunohistochemical analysis) have shown inconsistent associations with outcome. Fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH), immunohistochemical analysis, and DNA sequencing were compared in this study of 40 NSCLC samples from TKI-treated patients. Response rates were 12 of 19 in EGFR-mutant vs 1 of 20 EGFR wild-type tumors (P = .0001), 7 of 19 FISH+ vs 4 of 17 FISH– tumors (not significant [NS]), 5 of 16 CISH+ vs 6 of 21 CISH– tumors (NS), and 3 of 9 immunohistochemically positive vs 7 of 22 immunohistochemically negative tumors (NS). EGFR mutation was associated with improved progression-free survival (P = .0004). Increased copy number (FISH or CISH) and protein expression (immunohistochemical) did not independently predict outcome. Thus, EGFR sequence analysis was the only method useful for predicting response and progression-free survival following TKI therapy in NSCLC.en_US
dc.language.isoen_USen_US
dc.publisherOxford University Press (OUP)en_US
dc.relation.isversionofdoi:10.1309/AJCPST1CTHZS3PSZen_US
dc.relation.hasversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156055/en_US
dash.licenseLAA
dc.subjectEGFRen_US
dc.subjectNon–small cell lung carcinomaen_US
dc.subjectMutationen_US
dc.subjectFluorescence in situ hybridizationen_US
dc.subjectChromogenic in situ hybridizationen_US
dc.subjectImmunohistochemistryen_US
dc.subjectErlotiniben_US
dc.titleEGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistryen_US
dc.typeJournal Articleen_US
dc.description.versionAccepted Manuscripten_US
dc.relation.journalAmerican Journal of Clinical Pathologyen_US
dash.depositing.authorSholl, Lynette Marie
dc.date.available2017-05-18T15:42:11Z
dc.identifier.doi10.1309/AJCPST1CTHZS3PSZ*
dash.authorsorderedfalse
dash.contributor.affiliatedJackman, David M
dash.contributor.affiliatedLee, Charles
dash.contributor.affiliatedYeap, Beow
dash.contributor.affiliatedLindeman, Neal
dash.contributor.affiliatedJanne, Pasi
dash.contributor.affiliatedSholl, Lynette


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record